Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Abstract:

:Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sensitive methods to measure or detect such disease have been evaluated, including multi-parametric flow cytometry, PCR, next-generation sequencing and imaging modalities. The following literature review examines current methods for detecting and monitoring minimal or measurable residual disease (MRD) in the post-transplant setting. Improved methods for detecting MRD will refine the current definitions of remission and could guide treatment approaches.

journal_name

Bone Marrow Transplant

authors

Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

doi

10.1038/bmt.2015.164

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

2-12

issue

1

eissn

0268-3369

issn

1476-5365

pii

bmt2015164

journal_volume

51

pub_type

杂志文章,评审
  • Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.

    abstract::We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700743

    authors: Woo MH,Ippoliti C,Bruton J,Mehra R,Champlin R,Przepiorka D

    更新日期:1997-04-01 00:00:00

  • High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients.

    abstract::In a series of 74 patients with hematological malignancies undergoing allogeneic bone marrow or peri- pheral blood stem cell transplants from an HLA-identical sibling donor, four developed diffuse alveolar hemorrhage (DAH) between days 0 and 23 post transplant. Diagnosis was made by the radiographic finding of diffuse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701995

    authors: Raptis A,Mavroudis D,Suffredini A,Molldrem J,Rhee FV,Childs R,Phang S,Barrett A

    更新日期:1999-10-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

    abstract::The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.173

    authors: Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

    更新日期:2014-02-01 00:00:00

  • Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation.

    abstract::In a study of 63 allogeneic and autologous bone marrow transplants, patients were randomized to receive the IgM and IgA enriched intravenous immunoglobulin (IVIG) preparation (Pentaglobin). Pentaglobin has been postulated to have anti-endotoxin properties and one of the aims of the study was to measure endotoxin level...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Poynton CH,Jackson S,Fegan C,Barnes RA,Whittaker JA

    更新日期:1992-06-01 00:00:00

  • Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation.

    abstract::Acute hemorrhagic cystitis due to adenovirus infections may be more severe or protracted in immunocompromised patients. This patient with chronic graft-versus-host disease following allogeneic marrow transplantation for acute myelogenous leukemia developed painful hematuria due to adenovirus infection that failed to r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Cassano WF

    更新日期:1991-03-01 00:00:00

  • Evaluation of oxidative and antioxidative parameters in pediatric hematopoietic SCT patients.

    abstract::Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.145

    authors: Sabuncuoğlu S,Kuşkonmaz B,Uckun Çetinkaya D,Ozgüneş H

    更新日期:2012-05-01 00:00:00

  • Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

    abstract::This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mob...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.130

    authors: Tricot G,Cottler-Fox MH,Calandra G

    更新日期:2010-01-01 00:00:00

  • Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

    abstract::Lineage-specific chimerism studies are commonly obtained at several time points after nonmyeloablative hematopoietic cell transplantation to assess the tempo and degree of engraftment, and to monitor graft rejection. For patients who receive myeloablative transplants, the value of frequent chimerism analyses using sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.155

    authors: Doney K,Loken M,Bryant E,Smith A,Appelbaum F

    更新日期:2008-08-01 00:00:00

  • Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.

    abstract::This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

    更新日期:1990-05-01 00:00:00

  • Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura.

    abstract::The pathophysiology of thrombotic thrombocytopenic purpura (TTP) is not well understood. Recent studies have described a platelet aggregating factor which has been characterized as a calcium-dependent cysteine protease (calpain) in patients with TTP. A type of TTP, sometimes called secondary TTP, has been associated w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701928

    authors: Zeigler ZR,Kelton JG,Moore JC,Shadduck RK,Andrews DF,Nath R,Agha M

    更新日期:1999-09-01 00:00:00

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis.

    abstract::Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.256

    authors: Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

    更新日期:2016-12-01 00:00:00

  • Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.

    abstract::We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). The overall incidence of VOD was 28% (14/50). The incidence of VOD among ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ozkaynak MF,Weinberg K,Kohn D,Sender L,Parkman R,Lenarsky C

    更新日期:1991-06-01 00:00:00

  • Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

    abstract::Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Szer J,Grigg AP,Phillips GL,Sheridan WP

    更新日期:1993-02-01 00:00:00

  • Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.

    abstract::Acute GVHD remains a major problem in allogeneic BMT, in particular when donors other than HLA-identical siblings are used. To determine the efficacy of an immunomagnetic method for depletion of CD4+ and CD8+ lymphocytes from the marrow graft, a series of 15 patients was studied. Thirteen patients had matched unrelate...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Jansen J,Hanks S,Akard LP,Thompson JM,Burns S,Chang Q,English D,Garrett P

    更新日期:1996-03-01 00:00:00

  • Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.

    abstract::We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705922

    authors: Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

    更新日期:2008-03-01 00:00:00

  • Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.

    abstract::Increased understanding of minor histocompatibility complex (MiHC) antigen presentation to donor T cells may permit methods to modulate graft-versus-host disease (GVHD), a major complication of allogeneic bone marrow transplantation (BMT). Previously, we described the importance of B cells as antigen presenting cells ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schultz KR,Paquet J,Bader S,HayGlass KT

    更新日期:1995-08-01 00:00:00

  • Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.

    abstract::The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.100

    authors: Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

    更新日期:2013-11-01 00:00:00

  • Social outcome in children treated by haematopoietic cell transplant for congenital immunodeficiency.

    abstract::Previous studies have reported increased rates of social difficulties in children treated by haematopoietic cell transplant (HCT). This study assessed social functioning in children with congenital immunodeficiency treated by HCT and investigated two potential underlying mechanisms that may explain social difficulties...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.318

    authors: Skucek E,Butler S,Gaspar HB,Titman P

    更新日期:2011-10-01 00:00:00

  • rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells.

    abstract::Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704711

    authors: Lassailly F,Sielleur I,Blaise D,Chabannon C

    更新日期:2005-01-01 00:00:00

  • Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

    abstract::The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2010.249

    authors: Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

    更新日期:2011-08-01 00:00:00

  • Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

    abstract::Hematopoietic cell transplantation (HCT) has become an established standard of care for many older patients with hematologic malignancies. The effect of transplantation on the quality of life (QOL) of older patients, however, has not been well studied. We thus analyzed QOL in patients ⩾60 undergoing an allogeneic HCT ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2014.166

    authors: Hamilton BK,Rybicki L,Dabney J,McLellan L,Haddad H,Foster L,Abounader D,Kalaycio M,Sobecks R,Dean R,Duong H,Hill BT,Bolwell BJ,Copelan EA

    更新日期:2014-11-01 00:00:00

  • Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.

    abstract::Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704728

    authors: Krejci M,Buchler T,Hajek R,Svobodnik A,Krivanova A,Pour L,Adam Z,Mayer J,Vorlicek J

    更新日期:2005-01-01 00:00:00

  • Health-care professionals' perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation.

    abstract::The majority of adult patients have sexual concerns after post-haematopoietic cell transplantation. Even so, health-care professionals (HCP) do not routinely discuss these problems. We, therefore, surveyed all the members of the European Society for Blood and Marrow Transplantation to evaluate the barriers and facilit...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-017-0027-y

    authors: Eeltink CM,Witte BI,Stringer J,Liptrott S,Babic A,Greenfield DM,Salooja N,Incrocci L,Visser O,Verdonck-de Leeuw IM,Duarte RF,Zweegman S

    更新日期:2018-03-01 00:00:00

  • 'Fetal' erythropoiesis following bone marrow transplantation as estimated by the number of F cells in the peripheral blood.

    abstract::The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

    更新日期:1994-11-01 00:00:00

  • Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion complicating stem cell transplantation.

    abstract::Hyponatremia is a common electrolyte disorder in hospitalized patients. Although there are a few case reports of hyponatremia following stem cell transplantation (SCT), no reports concerning the incidence are currently available. We describe the occurrence of hyponatremia and the syndrome of inappropriate secretion of...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704688

    authors: Kobayashi R,Iguchi A,Nakajima M,Sato T,Yoshida M,Kaneda M,Suzuki Y,Mino E,Kuroki F,Kobayashi K

    更新日期:2004-12-01 00:00:00

  • Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.

    abstract::Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34(+) cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 10(6) CD34(+) ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.74

    authors: Chen AI,Bains T,Murray S,Knight R,Shoop K,Bubalo J,Fowler C,Slater S,Maziarz RT

    更新日期:2012-12-01 00:00:00

  • Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.

    abstract::Acquired factor VII (FVII) deficiency in the absence of vitamin K deficiency, oral anticoagulant therapy, synthetic liver dysfunction, or DIC is rare, with only a handful of cases thus far reported. In the period from 1990 to 1996 we identified eight patients with acquired FVII deficiency, all of whom presented with p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703381

    authors: Toor AA,Slungaard A,Hedner U,Weisdorf DJ,Key NS

    更新日期:2002-03-01 00:00:00

  • FK506-associated limbic injury following umbilical cord blood transplantation.

    abstract::A 5-year-old girl with Ph-positive chronic myelogenous leukemia, who underwent umbilical cord blood transplantation, developed two episodes of electrical status epilepticus while receiving tacrolimus (FK506) then cyclosporin A (CsA), as treatment against graft-versus-host disease. MRI including diffusion weighted MR i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704168

    authors: Yoshida Y,Shimada H,Mori T,Yoshihara H,Takeoka M,Takahashi T

    更新日期:2003-09-01 00:00:00

  • Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.

    abstract::Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Ho AD,Thaler J,Willemze R,Lauria F,Derossi G,Kuse R,Stryckmans P,Blanc CM,Cataldo F,McVie G

    更新日期:1989-01-01 00:00:00

  • Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields.

    abstract::Forty seven patients with hematological malignancies were treated with high doses of cytosine arabinoside (Ara C; 12 g/m2) and etoposide (VP-16), followed by recombinant human granulocyte colony-stimulating factor (rhG-CSF; 50 micrograms/m2). Peripheral blood progenitor cells (PBPC) were collected during rapid leukocy...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Shimazaki C,Yamagata N,Tatsumi T,Hirata T,Oku N,Ashihara E,Goto H,Inaba T,Fujita N,Haruyama H

    更新日期:1995-05-01 00:00:00